|Videos|May 4, 2020

Dr. Desai Sheds Light on COVID-19 Risk Among Patients With Cancer

Aakash Desai, MD, MPH, provides additional insight into his research on COVID-19 risk and patients with cancer and shed light on how institutions are taking action against the virus.

Please visit www.OncLive.com to watch the entitreity of the MJH Life Sciences News Network, which provides the latest news across a variety of healthcare specialties, and a number of interviews with experts in the medical field, many of which are focused on the ongoing COVID-19 pandemic.

Stay up to date on the most recent and practice-changing oncology data

Related to this article

July 21st, 2026

Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL

High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.

Melanoma | Image Credit: © Maris - stock.adobe.com

July 20th, 2026

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.

Head and neck cancer | Image Credit: © Creative Station - stock.adobe.com

July 20th, 2026

Roswell Park to Spotlight Advances in AI, Immunotherapy and Surgery at International Head/Neck Cancer Meeting

Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.

SCAC | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

July 20th, 2026

FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC

Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.

Allo-HSCT | Image Credit: © LASZLO - stock.adobe.com

July 20th, 2026

Older Age Is Independently Associated With Inferior Survival After PTCy-Based Unrelated Donor HSCT in Hematologic Malignancies

Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.

DLBCL | Image Credit: © Bipul Kumar - stock.adobe.com

July 20th, 2026

META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL

The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

July 19th, 2026

Five Under 5: Top Oncology Videos for the Week of 7/12

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

July 18th, 2026

The OncFive: Top Oncology Articles for the Week of 7/12

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Dr. Desai Sheds Light on COVID-19 Risk Among Patients With Cancer

Related to this article

Trending on OncLive

FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL

Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL

Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL